Advice
Following a full submission
agomelatine (Valdoxan) is not recommended for use within NHS Scotland for the treatment of major depressive episodes in adults.
When used in a flexible dosing schedule, agomelatine significantly reduced the symptoms of depression and increased the number of patients who responded to treatment compared with placebo. There are limited comparative data against existing antidepressants and the results of such comparisons are variable.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
The licence holder has indicated their intention to resubmit.
Download detailed advice102KB (PDF)
Medicine details
- Medicine name:
- agomelatine (Valdoxan)
- SMC ID:
- 564/09
- Indication:
- Major depressive episodes
- Pharmaceutical company
- Servier Laboratories Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 09 November 2009